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Abstract: Objectives: To evaluate the effects of folic acid supplementation on isolated oral 
cleft recurrence and fetal growth. Patients and Methods: The study included 2,508 women 
who were at-risk for oral cleft recurrence and randomized into two folic acid 
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supplementation groups: 0.4 and 4 mg per day before pregnancy and throughout the first 
trimester. The infant outcome data were based on 234 live births. In addition to oral cleft 
recurrence, several secondary outcomes were compared between the two folic acid groups. 
Cleft recurrence rates were also compared to historic recurrence rates. Results: The oral 
cleft recurrence rates were 2.9% and 2.5% in the 0.4 and 4 mg groups, respectively. The 
recurrence rates in the two folic acid groups both separately and combined were 
significantly different from the 6.3% historic recurrence rate post the folic acid fortification 
program for this population (p = 0.0009 when combining the two folic acid groups). The 
rate of cleft lip with palate recurrence was 2.9% in the 0.4 mg group and 0.8% in the 4 mg 
group. There were no elevated fetal growth complications in the 4 mg group compared to 
the 0.4 mg group. Conclusions: The study is the first double-blinded randomized clinical 
trial (RCT) to study the effect of high dosage folic acid supplementation on isolated oral 
cleft recurrence. The recurrence rates were similar between the two folic acid groups. 
However, the results are suggestive of a decrease in oral cleft recurrence compared to the 
historic recurrence rate. A RCT is still needed to identify the effect of folic acid on oral 
cleft recurrence given these suggestive results and the supportive results from previous 
interventional and observational studies, and the study offers suggestions for such future 
studies. The results also suggest that high dosage folic acid does not compromise fetal growth. 
Keywords: oral clefts; cleft lip; cleft palate; birth defects; folic acid; vitamins; prevention; 
pregnancy; nutrition; Brazil 
ClinicalTrials.gov Identifier: NCT00397917 
 
1. Introduction 
Oral clefts are among the most common birth defects worldwide, with incidence ranging from 
1/200 births in Amerindian populations to about ½,500 births in African populations and an 
intermediate incidence for European populations at about 1/700 births [1]. In addition to the short-term 
health consequences and healthcare costs due to reduced fetal growth [2] and the need for surgical 
repair, oral clefts have long-term adverse effects on health requiring dental, speech, and psychosocial 
interventions and increase hospitalization risks up to adulthood [3]. Oral clefts significantly reduce the 
quality of life of affected children and their families [4,5]. 
The etiology of oral clefts is complex involving genetic and environmental factors with both 
independent and interactive effects. Although much of the genetic etiology, particularly functional and 
developmental pathways, remain unknown, several genes/loci have been implicated in oral clefts [6–9], 
with most compelling evidence for IRF6 and loci near 8q24, MAFB, ABCA4 and VSX1 [8,10]. 
Several environmental/behavioral factors may play a role particularly smoking, which may have both 
independent [9] and interactive effects with genetic risk factors [11], and folate/multivitamin use [12].  
There has been a wide interest in evaluating the role of maternal nutrition particularly the 
consumption of folate rich diets and use of folic acid supplements in oral cleft recurrence and 
occurrence. A detailed review of this literature is presented elsewhere [12]. Several observational 
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studies provide supportive evidence for a protective effect of folate and folic acid supplementation on 
oral cleft occurrence. However, there is still a large uncertainty about the role of folic acid 
supplementation on occurrence because these observational studies might not entirely account for bias 
resulting from maternal self-selection into vitamin use and nutritional behaviors, which may be 
correlated with unobserved health or behavioral characteristics that affect oral cleft risks.  
The risk of oral cleft recurrence, defined as the occurrence of oral clefts in already affected families 
(i.e., mother is affected or has had a previous child with oral clefts) is higher by about 40 times than 
overall prevalence in the general population (4–5% versus 1/1,000, respectively). Several studies have 
evaluated the effects of folic acid supplementation, particularly high versus low doses on oral cleft 
recurrence. Most of these studies found significant protective effects of high doses—on average a 
decrease of 50% in recurrence (see detailed review in [12]). However, unlike the evidence for a 
preventive effect on neural tube defect (NTD) recurrence [13], the evidence for a preventive effect on 
oral cleft recurrence is still controversial, mainly because none of the previous interventional studies 
used a randomized design and as a result were still prone to bias by lacking an appropriate control 
group. Another limitation of some studies was the challenge involved in evaluating folic acid effects 
independent of other vitamins. 
The Oral Cleft Prevention Program (OCPP) was as a double blinded RCT to assess the effect of 
high-dose versus low-dose folic acid supplementation on oral cleft recurrence among children of 
Brazilian women [14]. We describe the OCPP’s design and report the findings as of December 2009 
after the trial was halted due to lower than expected enrollment and pregnancy rates among study 
participants. We also compare the recurrence rates in the OCPP to a historic recurrence rate.  
In addition, we report data on fetal growth outcomes, compliance, and adverse events. The 
comparisons we present on fetal development outcomes between high and low folic acid 
supplementation groups are the first from a randomized study in humans. Finally, we provide insights 
based on the lessons learned from the OCPP for a future study that can provide a definitive answer 
about the effects of high dose folic acid on oral cleft recurrence. 
2. Methods 
2.1. Design 
This study aimed at testing the effect of 4 mg folic acid taken daily before pregnancy throughout the 
first trimester by women who were themselves born with a cleft or had had a prior child with a cleft on 
recurrence of clefting in a subsequent child compared to taking the currently recommended 0.4 mg 
dose [14]. A placebo control group was not used, as a low dose of folic acid had already been 
recommended as a standard vitamin therapy for women during preconception and pregnancy period 
for prevention of NTDs. 
The study had a double-blinded randomized design, where both investigators and participants were 
blinded to the study group assignment [14]. Participants were randomly assigned before pregnancy to 
the two study groups of taking 4 mg or 0.4 mg pills of folic acid that were identical in appearance. 
Randomization occurred at the participant level and was stratified by the study site to ensure a 
balanced representation in both treatment groups. The study Data Center at RTI International oversaw 
the randomization and generated the randomization sequence using permuted blocks of random size. 
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The randomization sequence linked the treatment assignment (0.4 mg or 4 mg) to a sequential list of 
serial numbers that were affixed to the study pill boxes under the supervision of the Data Center. The 
pillboxes were also numbered in order of dispensing (1, 2, 3, etc.). The folic acid pills were 
specifically manufactured for the study by ATIVUS Pharmaceutical Industries in Brazil. The 
manufacturer conducted quality control tests for each batch of pills including identification test of the 
raw folic acid material used in the pills (prior to production), assay tests for the folic acid dosage in the 
pills, content uniformity tests (to ensure that the dosage is consistent across pills), and dissolution tests to 
ensure that the pills dissolve adequately in a standard time. 
Participants who had a delay in menstruation of 14 days or more at baseline underwent a pregnancy 
test before randomization; only those with a negative test were randomized [14]. After randomization, 
all participants were asked to take a single pill of 4 mg or 0.4 mg of folic acid daily throughout the first 
trimester of pregnancy if they became pregnant or until end of participation in the study if they did not 
become pregnant. Participants were followed up every two months to check on their health status, 
provide new pill boxes for the next two months, and collect old pillboxes with any unused pills to 
measure compliance. During the first two years of the study (between 2004 and 2006), bimonthly 
follow-ups were completed in person. In later years, bimonthly follow-ups were mostly completed 
over the phone and study pills delivered to participants through express mail. When participants were 
available, periodic in-person follow-ups were conducted every six months. Compliance was evaluated 
by counts of unused pills from returned pillboxes. An average compliance rate per participant was 
generated from all the returned pillboxes for that participant. Serum and RBC folate levels, evaluated 
periodically after randomization in 2004–2006 and after 12 months of randomization (or at pregnancy, 
whichever occurred first) beginning in 2007 also provided another measure of compliance. Folate 
levels were not communicated with the subjects and were seen and entered by staff not directly 
involved with the study subjects. 
Participants confirmed to be pregnant were advised by the study staff to stop taking the study pills 
at the end of the first trimester of pregnancy [14]. There were no restrictions on participants taking 
other supplements and vitamins before or during pregnancy as recommended by their physicians. The 
study staff attempted to follow pregnant participants periodically (usually every two months) over the 
phone to check on pregnancy progress. Furthermore, the study staff attempted to maintain contact with 
the participants’ prenatal care providers to check on pregnancy progress. 
After delivery, all live births were followed in-person by the study staff to measure oral cleft status. 
Mothers also completed an interview with the study staff after delivery either in-person or over the 
phone to obtain data on perinatal and infant health outcomes [14]. All interviews after delivery 
occurred within 2 years after birth; ~90% occurred within 6 months after delivery; another 9% 
occurred before the end of first year of life. The participants’ physicians were also interviewed after 
delivery when possible to obtain data on the occurrence of oral clefts and birth defects and abnormal 
delivery events. Participants and physicians were also interviewed after miscarriages/stillbirths to 
obtain data on birth defects. However, no data were available to measure the occurrence of birth 
defects and oral clefts in most miscarriage/stillbirth cases (there were only two stillbirth cases in the 
study). The study was designed from the beginning to focus on oral cleft occurrence in live births 
given the challenges of measuring these outcomes in miscarriages/stillbirths. 
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The OCPP aimed at observing 1,582 births (791 births in each folic acid group) in order to achieve 
80% power for a 50% reduction in a baseline rate of 5% recurrence. The study assumed a birth rate of 
0.0957 births per participant-year, which implied that about 16,531 participant-years were required to 
observe the 1,582 births. 
2.2. Recruitment and Ethics Approvals 
All potential participants were screened for eligibility using the same data forms and inclusion 
criteria across all sites by trained and qualified study staff before they were enrolled [14]. After 
confirming eligibility, the study staff asked the women to consent. For illiterate participants, 
confirmation was obtained as a thumbprint in the presence of a witness (only 10 participants reported 
no formal schooling). The study staff assured all women that refusal to participate in the study would 
in no way affect further treatment or care at the clinic. All interviews, informed consents, and data 
collection forms were in Portuguese. The study protocol, informed consent, manual of operations, and 
data collection forms were approved by the ethics committees of the study sites and by CONEP, the 
national committee of research ethics in Brazil. 
2.3. Study Population 
The study was conducted at six craniofacial clinics in Brazil (see detailed list in online Appendix). 
The clinics were selected based on their long experience in providing care to patients with oral clefts 
and most of them are considered referral centers for oral cleft care. Participants were identified from 
the population of patients served by these clinics. Enrollment was first initiated in 2004 using an 
outreach model for the patient pool served by the first study clinic. In that model, the study staff 
conducted meetings with the study participants in their local communities during which data were 
collected and study pills provided. In 2005, a clinic-based recruitment model was initiated at two new 
sites, where participants were recruited and interviewed at the study clinic. The clinic-based model 
collected data from participants over phone interviews and mostly delivered study pills via express 
mail; in-person follow-ups were completed with the participant every 6 months when possible.  
In 2007, the first site switched from the outreach model to a clinic-based model, and two new sites 
were added under the clinic-based model. A sixth site following the clinic-based model was added in 2008. 
2.4. Inclusion Criteria 
The study participants were women 16–45 years of age who have nonsyndromic/isolated oral clefts 
or had had at least one natural child of any age with nonsyndromic/isolated oral clefts who and who 
had received care at the study clinics [14]. The study participants also resided in the study catchment 
area consisting of the state where the clinic is located and surrounding states. During the first two years 
of the study (2004–2006) in the outreach model, both cleft lip with/without palate as well as cleft 
palate only were included in the study. Beginning in 2006, new recruitment was limited to cases of 
cleft lip with or without cleft palate, and cases with cleft palate only were no longer enrolled. The 
reason was to avoid any potential confounding effects of cleft palate only which is commonly 
separated from cleft lip with/without cleft palate in studies of cleft etiology, even though there may be 
overlap in etiology and recurrence prevention. 
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2.5. Exclusion Criteria 
Participants who met any of the following criteria at the time of screening were excluded from 
participation [14]: 
1. Syndromic/non-isolated cleft status including cases with recognized syndromes, cases with a 
chromosome abnormality, cases with one or more other major structural anomaly, cases with 
cognitive delay (IQ or equivalent less than 80), or cases exposed to phenytoin or valproic 
acid in utero. 
2. Any first degree relative (that is a parent, sibling or child) who has cleft palate only (this was 
added in 2007 when new enrollment was limited to participants who are themselves affected 
or have affected children with cleft lip with/without palate). 
3. The woman or her husband/partner was sterilized (such as tubal ligation). 
4. Using intrauterine devices or injectible contraceptives (added in 2008). 
5. Using anti-epileptic drugs (since the metabolism of anti-epileptic drugs requires a great deal 
of folic acid). 
6. Using drugs that contain benzodiazepines (as these may increase the risk for birth defects 
and oral clefts). 
7. Women who were pregnant at screening. 
8. Women who were planning to move outside of the catchment area of the study within the 
next year. 
9. Women who had B12 deficiency as determined from testing participants’ blood samples in 
the study before supplementation (B12 level below 174 pg/mL or 134.328 pmol/L), which 
may be masked by folic acid. 
10. Women who were allergic to folic acid. 
Participants who did not meet these criteria at enrollment because these were missed during the 
initial screening or the subject met these criteria after enrollment but were later found to meet the 
following exclusion criteria were discontinued from participation: definite sterilization of the woman 
and/or husband/partner, detecting B12 after randomization and a hematologist recommended that the 
woman be fully withdrawn from the study (no participants met this criterion), and taking epileptic 
drugs unless the participant is pregnant. B12 levels were assessed every 4 months between 2004 and 
2006. After that, B12 levels were assessed once every 12 months. 
2.6. Study Outcomes 
The primary outcome of the study was the recurrence of isolated oral clefts, defined as the birth of a 
child with an oral cleft to the study women during their participation [14]. This is considered 
recurrence since only women who are themselves affected with oral clefts or have had a previous child 
with an oral cleft are enrolled in the study. The study infants were examined in person by a trained 
study staff to check and document oral clefting status and look for evidence of associated syndromes. 
The study evaluated several secondary outcomes. The cleft recurrence rates in the OCPP were 
compared to historic recurrence rates. We calculated these rates by surveying women who are 
themselves affected or have had children affected with isolated cleft lip with/without cleft palate who 
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were obtaining care from the same clinics involved in the OCPP but who did not enroll in the OCPP 
for reasons unrelated to cleft recurrence risk (such as sterilization and refusal to participate). Only 
cases with cleft lip with/without cleft palate were included in the historic recurrence survey; cases with 
cleft palate only were excluded. The study staff interviewed these women in 2011–2012 for their 
complete pregnancy history. We calculated the historic recurrence rates for the period after the 
initiation of the folic acid fortification program (after 2004) since the OCPP infants were born during 
this period and fortification may affect oral cleft recurrence. For affected women, the recurrence rate 
was defined as the proportion of affected children among all live births. For unaffected women with an 
affected child, the recurrence rate was defined as the proportion of affected children among all live 
births after the affected child. 
The severity of oral clefts, birth weight, gestational age, and preeclampsia were also evaluated as 
secondary outcomes. In addition, we report here a comparison of head circumference, length at birth, 
and Apgar scores between the study births in the two folic acid groups. 
2.7. Statistical Analysis 
Outcomes were compared between the two doses of folic acid to which the women were assigned 
randomly at enrollment. Data for all women and infants were analyzed in the treatment arm to which 
the women were randomized, even when the women did not comply fully with the assigned treatment 
regimen as described above. We recognize that the sample size does not provide adequate power to 
identify moderate effects for small frequency outcomes when analyzing the live birth sample. Given 
the randomized design of the study, we compared the outcomes between the two folic acid groups 
using two-group comparison tests including a Fisher’s exact test for binary outcomes and a Student’s  
t-test for continuous outcomes. A Wilcoxon rank-sum (or Mann-Whitney) test was also used for the 
continuous outcomes since they did not meet normality tests (except for head circumference). Fisher 
exact tests and student’s t-tests were also used to compare the baseline characteristics between the two 
folic acid groups. We compared the OCPP recurrence rates to the historic rates using a one-sample  
z-test for proportions. 
At the beginning of the study, there was no limit on how long a woman may participate. 
Participants were allowed to enroll again in the study in the same treatment group after their pregnancy 
if they wished to do so and if they still met all the eligibility criteria. Nine women participated a 
second time and had live births. In 2008, participation time was limited to three years. The study 
participants participated in the study until their delivery if they became pregnant or until they had 
completed three years of participation without becoming pregnant. After delivery, the participants 
were allowed to participate again if they had not completed a total of three years of participation in the 
study. We first report the analyses only for first-enrollments and first pregnancies. In additional 
analyses of cleft recurrence, we add women who participated a second time. 
3. Results 
3.1. Sample Description 
Between January 2004 and May 2009, a total of 3,821 women were screened for eligibility into the 
study. Of these, 851 (22.3%) met one or more of the study exclusion criteria. Of the 2,970 eligible 
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women, 2,508 women gave consent and were randomized into the study treatment and control groups; 
the 462 who were not randomized did not consent to participate in the study. Of the randomized 
women, 273 became pregnant during their first participation in the study. Of these pregnancies, there 
were 269 verifiable pregnancy outcomes (miscarriage, still birth or live birth); 234 were live births,  
33 were miscarriages, and two were still births. Of these live births, 225 live births occurred in families 
where the previous affected child or affected mother had cleft lip with/without cleft palate (but not 
cleft palate only). Of the randomized women, 913 chose to discontinue their participation in the study 
before pregnancy, and five pregnant women were lost to follow up. On average, these women 
withdraw 20 months after randomization (ranging from 0 to 57). Figure 1 shows a flow diagram for 
study screening, enrollment/randomization, withdrawal, and pregnancy occurrence and outcome status. 
The average participation length was 20 months and ranged from 0 to 72 months. 
Figure 1. Study flow diagram. 
 
Notes: Pregnancy and outcome counts are based on first time enrollments only. The pregnancy outcome 
count in the 0.4 mg group includes twin births. 
In 2009, the DSMB overseeing the study with the funding institute (NIDCR) recommended that all 
new recruitment be halted and enrollment of non-pregnant women participating in the study be ended 
due to the lower than anticipated enrollment and pregnancy rates, which implied that the sample of 
infants needed to achieve 80% power could not be reached over the planned project period. Therefore, 
the enrollment of all non-pregnant participants was terminated at all sites after that. All pregnant 
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women were followed according to the protocol and their babies examined in person by a trained study 
staff while maintaining the blinding of the subject and study staff to the folic acid group assignment. 
Table 1 compares the distributions of baseline clinical, demographic and socioeconomic 
characteristics of all randomized women between the two folic acid groups. There were no statistically 
significant differences in these variables between the two folic acid groups. Of the randomized sample, 
about 41% were women who are themselves affected with oral clefts and had no children at the time of 
enrollment; about 59% were unaffected mothers with affected children; affected mothers with affected 
children were less than 1%. About 77% of the affected patients (either participants or their children) 
had cleft lip with palate, and about 21% had cleft lip only. The sample had overall low socioeconomic 
status with about 40% of the participants having only fundamental or no education and 51% having 
intermediate education; about 49% of the sample were employed. There were no significant 
differences between the two groups in baseline serum and RBC folate levels measured at enrollment 
before supplementation. 
Table 1. Baseline confounders by treatment. 
Demographic Variable 
0.4 mg 
Folic Acid 
4.0 mg 
Folic Acid 
p-Value Total 
Subjects, N 1,251 1,257  2,508 
Cleft status group, n (%) 1,251 1,257 0.6437 2,508 
Affected mother without children 502 (40.1) 518 (41.2)  1,020 (40.7) 
Unaffected mother of affected children 742 (59.3) 729 (58.0)  1,471 (58.7) 
Affected mother with affected children 7 (0.6) 10 (0.8)  17 (0.7) 
Family cleft type, n (%) 1,233 1,238 0.4733 2,471 
Cleft lip 243 (19.7) 268 (21.6)  511 (20.7) 
Cleft palate 36 (2.9) 33 (2.7)  69 (2.8) 
Cleft lip with cleft palate 954 (77.4) 937 (75.7)  1,891 (76.5) 
Age, n (%) 1,243 1,253 0.5682 2,496 
<20 229 (18.4) 204 (16.3)  433 (17.3) 
20–29 625 (50.3) 646 (51.6)  1,271 (50.9) 
30–39 356 (28.6) 370 (29.5)  726 (29.1) 
≤40 33 (2.7) 33 (2.6)  66 (2.6) 
Marital status, n (%) 1,247 1,257 0.6058 2,504 
Single 422 (33.8) 414 (32.9)  836 (33.4) 
Married or stable relationship 801 (64.2) 812 (64.6)  1,613 (64.4) 
Divorced or widowed 24 (1.9) 31 (2.5)  55 (2.2) 
Highest level of schooling, n (%) 1,174 1,176 0.1423 2,350 
Fundamental or none 432 (36.8) 427 (36.3)  859 (36.6) 
Intermediate 616 (52.5) 592 (50.3)  1,208 (51.4) 
University 126 (10.7) 157 (13.4)  283 (12.0) 
Employed in the past month, n (%) 1,174 1,176 0.4336 2,350 
Yes 579 (49.3) 561 (47.7)  1,140 (48.5) 
No 595 (50.7) 615 (52.3)  1,210 (51.5) 
Smoke cigarettes, n (%) 1,247 1,257 0.8070 2,504 
Yes 139 (11.1) 144 (11.5)  283 (11.3) 
No 1,108 (88.9) 1,113 (88.5)  2,221 (88.7) 
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Table 1. Cont. 
Demographic Variable 
0.4 mg 
Folic Acid 
4.0 mg 
Folic Acid 
p-Value Total 
Drink alcoholic beverages, n (%) 1,246 1,257 0.1103 2,503 
Yes 145 (11.6) 173 (13.8)  318 (12.7) 
No 1,101 (88.4) 1,084 (86.2)  2,185 (87.3) 
Multivitamin Use, n (%) 876 888 0.6271 1,764 
Did not take multivitamin 801 (91.4) 825 (92.9)  1,626 (92.2) 
1 to 3 times a week 7 (0.8) 5 (0.6)  12 (0.7) 
4 to 6 times a week 2 (0.2) 3 (0.3)  5 (0.3) 
Every day of the week 66 (7.5) 55 (6.2)  121 (6.9) 
Baseline Serum Folate (ng/mL) 1,211 1,211  2,422 
Mean (SD) 11.4 (5.1) 11.9 (8.8) 0.0650 11.6 (7.2) 
Median 10.7 10.7 0.8838 10.7 
Baseline Red Cell Folate (ng/mL) 1,150 1,156  2,306 
Mean (SD) 606.7 (451.6) 595.9 (387.2) 0.5390 601.3 (420.5) 
Median 573.5 581.0 0.8658 577.5 
Note: Some observations had missing data on certain measures. 
3.2. Cleft Recurrence and Secondary Outcomes 
Table 2 shows the cleft recurrence and type in the OCPP focusing first on families where the 
previously affected child or affected mother had cleft lip with/without cleft palate but not cleft palate 
only and on first-time enrollments. The cleft recurrence rate was 2.9% (three affected out of 105 births) 
in the 0.4 mg folic acid group and 2.5% (three affected out of 120 births) in the 4 mg group (p = 0.59 
based on a one-sided Fisher’s exact test). The total recurrence rate combining the two folic acid groups 
was 2.7% (six affected out of 225 infants). One of the live births in the 4 mg group was diagnosed with 
Van-der-Woude syndrome (VWS), which is the most common syndromic form of oral clefting with a 
dominant genetic inheritance model [15] and about 50% recurrence risk. 
Table 2. Cleft recurrence and types in OCPP. 
Outcomes 
0.4 mg 
Folic Acid 
4.0 mg 
Folic Acid 
Total 
Infants delivered, n 105 120 225 
Recurrence of oral clefts, n (%) 3 (2.9) 3 (2.5) 6 (2.7) 
Cleft type, n (%) 
Cleft lip only 0 (0.0) 1 (0.8) 1 (0.44) 
Cleft palate only 0 (0.0) 1 (0.8) 1 (0.4) 
Cleft lip with palate 3 (2.9) 1 (0.8) 4 (1.8) 
Notes: This is based on first time enrollment births only where previous 
affected child or affected mother had cleft lip with/without cleft palate 
(but not cleft palate only). One case with cleft lip only in the 4 mg group 
had Van-der-Woude syndrome (missed at maternal screening); 
excluding this case results in recurrence of 1.6%. 
Int. J. Environ. Res. Public Health 2013, 10 600 
 
 
VWS was not diagnosed when the mother of this case was screened for eligibility before enrollment 
and should have been excluded. Excluding the VWS case results in an isolated oral cleft recurrence 
rate of 1.6% (p = 0.44). All three cleft cases in the 0.4 mg group were cleft lip with palate compared to 
one case in the 4 mg group; the rates of cleft lip with palate rates were 2.9% versus 0.8% in the 0.4 and 
4 mg groups, respectively. Adding the births from families where the previously affected child or 
affected mother had cleft palate only or including the babies of mothers who participated a second time 
(i.e., only including cases that qualified because of the first affected child or mother having cleft lip 
with or without cleft palate) has virtually no effect on the estimates of oral cleft recurrence as only a few 
cases are added as shown in Supplementary online Table 1.1 (the same 6 affected cases were observed). 
Table 3 shows the calculated recurrence rates in the historic control group. Data were obtained on 1,238 
at-risk children born subsequent to an affected child (722 children) or to an affected mother (516 children). 
Table 3. Historic recurrence rates in Brazil post-fortification. 
Group 
Total 
births 
Affected Rate (%) 
Any period 
Sibling affected 722 48 6.65 
Mother affected 516 36 6.98 
Post-fortification period 
Sibling affected 278 18 6.47 
Mother affected 50 3 6.00 
We compared the OCPP rates first to the recurrence rate in the total historic group, and then to the 
recurrence rate in children exposed to the fortification program during the first trimester of pregnancy 
in order to account for any change in recurrence with fortification since women were randomized into 
the OCPP after the beginning of the fortification. The overall recurrence rate was 6.65% for having a 
prior affected sibling and 6.98% for affected mothers; these rates were fairly similar when restricting 
the sample to children exposed to the fortification program (6.47% for a prior affected sibling and 
6.0% for affected mothers). Based on these historic recurrence rates and the proportions of affected 
women versus unaffected mothers of affected children, we calculated the “expected” historic 
recurrence rates for the OCPP groups for the births from the first time enrollments and whose 
previously affected sibling or mother had cleft lip with/without cleft palate (but not cleft palate only) 
and compared them to the observed rates in Table 4. The expected recurrence rate among OCPP live 
births was about 6.8% when using the overall historic recurrence rate, and about 6.3% when using the 
post-fortification historic recurrence rate. These expected rates were more than twice as the observed 
ones for both folic acid groups and were significantly different from the observed rates in the OCPP 
folic acid groups both separate and combined (p = 0.0009 when comparing the post-fortification 
expected recurrence rate to the observed recurrence rate in the combined group).  
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Table 4. Expected versus observed recurrence rates in OCPP. 
RCT group Expected historical recurrence rate (%) 
Observed 
recurrence rate (%) p-value 
Compared to overall historic recurrence rate 
0.4 folic acid group 6.8 a 2.9 0.0172 
4 mg folic acid group 6.8 b 2.5 0.0026 
Both 0.4 and 4 mg groups 6.8 c 2.7 0.0001 
Compared to historic recurrence rate post-fortification 
0.4 folic acid group 6.3 e 2.9 0.0379 
4 mg folic acid group 6.3 f 2.5 0.0077 
Both 0.4 and 4 mg groups 6.3 g 2.7 0.0009 
Note: Expected historical rates are calculated based on the historical rates from the recurrence 
study weighted by the proportions of babies born into each group (affected and unaffected 
mothers). Observed rates are based on first time enrollment births only with previous affected 
child or affected mother with cleft lip with/without palate (but not cleft palate only).  
a ((37 × 6.98) + (68 × 6.65))/105; b ((54 × 6.98) + (66 × 6.65))/120; c ((91 × 6.98) + (134 × 
6.65))/225; e ((37 × 6.00) + (68 × 6.47))/105; f ((54 × 6.00) + (66 × 6.47))/120; g ((91 × 6.00) + 
(134 × 6.47))/225. 
Table 5 compares the other secondary outcomes between the two folic acid groups. There are no 
significant differences in infant’s mean birth weight, gestational age, length at birth, head circumference, 
and apgar scores between the two folic acid groups. Virtually similar results for differences in birth 
weight, length at birth, head circumference, and apgar scores between the two folic acid groups were 
observed when adjusted for gestational age using regression analysis, which is expected since there is 
no significant difference in gestational age between the two groups (detailed regression results 
available from the authors upon request). There was no significant difference between the two folic 
acid groups in preeclampsia (4.8% versus 3.7% in the 4 and 0.4 mg groups, respectively). 
Table 5. Secondary outcomes by treatment. 
Outcomes 0.4 mg Folic Acid 
4.0 mg 
Folic Acid p-value Total 
Birth weight (g), n 108 125  233 
Mean (SD) 3,228.8 (443.7) 3,159.9 (508.2) 0.2753 (0.4287) 3,191.8 (479.6) 
Gestational age (weeks),  108 123  231 
Mean (SD) 38.5 (1.6) 38.6 (2.1) 0.6590 (0.3929) 38.5 (1.9) 
Head Circumference (cm), n 87 102  189 
Mean (SD) 34.1 (1.4) 34.1 (1.8) 0.9075 (0.8427) 34.1 (1.6) 
Length (cm), n 107 120  227 
Mean (SD) 48.2 (2.5) 48.3 (2.6) 0.9036 (0.4521) 48.3 (2.6) 
Apgar score, n 73 86  159 
Median 9 9 (0.0868) 9 
Interquartile range 9–10 9–10  9–10 
Min-Max 2–10 8–10  2–10 
Preeclampsia, n 108 125 0.755 233 
Yes n (%) 4 (3.7) 6 (4.8)  10 (4.3) 
No n (%) 99 (96.3) 107 (95.2)  206 (95.7) 
Notes: The outcomes are for first time enrollment births only. Some observations had missing data on certain 
outcomes. The p values from the Wilcoxon rank-sum test are in brackets. 
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3.3. Compliance 
Based on the pill counts, median compliance was about 74% in both groups. The changes in blood 
folate levels also suggest good compliance with the study interventions. Based on a subgroup of 
participants with reviewed laboratory tests conducted at the laboratory at the study site at the Hospital 
de Clínicas de Porto Alegre for participants enrolled in the clinic-based model (total of 1,312 tests), 
mean post-supplementation serum folate levels were about 13.0 and 14.3 ng/mL in the 0.4 and 4 mg 
groups, respectively, representing an increase by about 1.7 and 3.1 ng/mL compared to the baseline 
levels (about 15% and 28%). The post-supplementation mean serum folate level was significantly 
higher in the 4 mg than 0.4 mg group (p < 0.0001). Similarly, post-supplementation mean RBC folate 
levels were about 716 and 793 ng/mL in the 0.4 and 4.0 mg groups (increase from baseline mean 
values of 712 ng/mL and 717 ng/mL, respectively, in this subgroup). Similar to serum folate, the  
post-supplementation mean RBC folate level was significantly higher in the 4 mg than 0.4 mg group  
(p = 0.0021). 
4. Discussion 
The study observes no difference in recurrence rates between the 4 mg and 0.4 mg groups. The 
small sample limits our ability to draw formal statistical inference on the effect of high dosage folic 
acid (4 mg) relative to low dosage (0.4 mg) on oral cleft recurrence based on comparing the recurrence 
rates between these two groups. With an observed recurrence rate of 2.9% in the 0.4 mg group, the 
current sample size provides 37% power to detect a 100% decrease—the maximum possible effect  
size —in recurrence in the 4 mg group based on a one-sided test (assuming that recurrence in the 4 mg 
group is equal to or less than that in the 0.4 mg) and a 5% type-1 error. However, at this sample size, 
the study has 80% power to detect a 6 percentage-point difference in recurrence between the two 
groups (i.e., 8.5% recurrence in the 0.4 mg group relative to 2.5% recurrence in the 4 mg group) based 
on a two-sided chi-square test and 5% type-1 error. Therefore at the current sample size, the study does 
not have statistical power to detect a smaller difference (<6 percentage-points) in recurrence rates 
between the two folic acid groups; a larger sample is needed to achieve acceptable power. In contrast, 
there was a decline in recurrence in both OCPP groups separate and combined compared to historic 
control groups. The study has reasonable power (65%) to detect the observed difference in recurrence 
in the combined sample of 0.4 and 4 mg groups compared to the post-fortification historic recurrence 
rate reported in Table 4 using a two-sided test and a 5% type-1 error (power of 80% using a one-sided 
test). The recurrence rates that can be detected in the individual folic acid groups as different from the 
post-fortification historic recurrence rate (at 80% power and based on a one-sided test and 5% type-1 
error) and can therefore be ruled out in this analysis are 1.6% in the 4 mg group and 1.4% in the 0.4 mg. 
The decrease in recurrence in the 0.4 mg group compared to the historic rate (similar to the 4 mg 
group) suggests that this dose may be effective in reducing cleft recurrence risk. However, more 
research is needed to test this hypothesis and quantify the effect. The relatively similar recurrence rates 
between the two folic acid groups may be due to the potential ineffectiveness of the higher dose in 
further reducing recurrence relative to the lower dose. This may also be complicated by the 
participants’ use of prenatal vitamins and folic acid supplements on their own as well as their dietary 
folate consumption. About 40% of the participants (based on data for 207 live births) reported using 
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multivitamins and/or folic acid supplements other than those supplied by the study during the month 
before pregnancy and/or during the first trimester (37% in the 0.4 mg and 43% in the 4.0 mg). Even 
though these additional folate sources would elevate the folate levels in both the 0.4 and 4 mg folic 
acid groups, they may result in an average folate intake in the lower dose group that is markedly higher 
than the 0.4 mg per day. 
One limitation of the study is introducing some changes in recruitment strategies (such as limiting 
length of participation to 3 years) and inclusion/exclusion criteria (such as not including cleft palate 
only and excluding women using injectable contraceptives) while the study was ongoing. Another 
limitation is the potential over-estimation of population recurrence risk based on the historic control 
groups since these were identified through craniofacial clinics providing care to patients with oral 
clefts. Therefore, women who have experienced a recurrence may have been overrepresented. This 
highlights the need to calculate these rates using population-based registries; however, these resources 
are relatively underdeveloped in Brazil and are currently not available for such efforts. These 
limitations should be considered when evaluating the generalizability of the study results. 
The study is the first to shed some light using a double-blinded randomized design on effects of 
high dosage folic acid on fetal development. The results suggest that high dosage folic acid does not 
compromise fetal growth or increase perinatal risks. These findings are consistent with previous 
observational study results suggesting positive effects of prenatal folic acid supplementation on 
development [16,17], and are opposite to recent results from a mice study reporting adverse effects on 
fetal growth. Furthermore, there were no significant differences in the rate and types of adverse events 
between the two groups (detailed results available upon request). Adverse events were regularly 
reported to the DSMB and IRBs and a member of the DSMB routinely reviewed all adverse events. 
There were no meaningfully elevated rates of adverse events in either group compared to expected 
population rates. These results suggest that high periconceptional folic acid supplementation may be a 
generally safe intervention for future studies. 
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Appendix 
List of Study Clinics 
 Hospital de Reabilitação de Anomalias Craniofaciais, Bauru, Sao Paulo 
 Hospital Santo Antônio: Obras Sociais Irmã Dulce, Salvador, Bahia 
 Instituto Materno Infantil Prof. Fernando Figueira, Recife, Pernambuco 
 Centro de Atendimento Integral ao Fissurado Lábio Palatal, Curitiba, Paraná 
 Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul 
 Fundação para Reabilitação das Deformidades Crânio-faciais, Lajeado, Rio Grande do Sul 
Table 1.1. Oral cleft recurrence outcomes for selected groups. 
Outcomes 
0.4 mg 
Folic Acid 
4.0 mg 
Folic Acid 
Total 
Adding births from families where previously affected child or mother had cleft palate only 
Recurrence of oral clefts, n (%) 109 125 234 
Yes 3 (2.8) 3 (2.4) * 6 (2.6) 
No 107 (97.2) 122 (97.6) 228 (97.3) 
Including births from first and second time enrollments 
Recurrence of oral clefts, n (%) 113 130 243 
Yes 3 (2.7) 3 (2.3) 6 (2.5) 
No 110 (97.3) 127 (97.7) 237 (97.5) 
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